 |
 |
 |
 |
 |
 |
|
||||||
|
| EDITOR | |||
 |
Neil Love, MD Medical Oncologist Editor, Lung Cancer Update for Nurses Research To Practice Miami, Florida |
 |
Beth Eaby, MSN, CRNP, OCN Outpatient Thoracic Oncology Nurse Practitioner Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania |
| FACULTY AFFILIATIONS | |||
 |
Alan B Sandler, MD Associate Professor of Medicine Medical Director, Thoracic Oncology Director, Vanderbilt-Ingram Cancer Center Affiliate Network Program Vanderbilt University Medical Center Division of Hematology/Oncology Nashville, Tennessee |
 |
Leslie Tyson, MS, APRN-BC, OCN Nurse Practitioner Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York |
 |
Ann Culkin, RN, OCN Thoracic Oncology Service Ambulatory Nursing Memorial Sloan-Kettering Cancer Center New York, New York |
 |
Jeanne Griffin, NP Nurse Practitioner Massachusetts General Hospital Cancer Center Boston, Massachusetts |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Lisa Aiello-Laws, RN, MSN, APN,C, AOCNS, John Brebner, Regina Seery Cunningham, PhD, RN, AOCN, Richard Kaderman, PhD, Joanne Librie, RN, Neil Love, MD, Douglas Paley, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Ginelle Suarez, Erin Wall and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS — salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:
Dr Sandler — Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi- Aventis; Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb Company, Cyclacel Pharmaceuticals Inc, Eli Lilly and Company, Genentech BioOncology, OSI Pharmaceuticals Inc, Pfizer Inc, Sanofi-Aventis, Wyeth; Speakers Bureau: Genentech BioOncology. Ms Culkin — Consulting Fees: Genentech BioOncology, OSI Pharmaceuticals Inc, Roche Laboratories Inc; Speakers Bureau: Eli Lilly and Company, NMCR Analytics. Ms Eaby — Speakers Bureau: Amgen Inc, Genentech BioOncology, Merck and Company Inc, Sanofi-Aventis. Ms Tyson — No financial interests or affiliations to disclose. Ms Griffin — No financial interests or affiliations to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
| Table of Contents | Top of Page |
